雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yi H, Akao Y, Maruyama W, Chen K, Shih J, Naoi M.	Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells	Journal of Neurochemistry	96 (2)	541- 549	2006
Shamoto-Nagai M, Maruyama W, Yi H, Akao Y, Tribl F, Gerlach M, Osawa T, Riederer P, Naoi M.	Neuromelanin induces oxidative stress in mitochondria through release of iron; mechanism behind the inhibition of 26S proteasome	Journal of Neural Transmission		In press	2006
Matsumoto K, Akao Y, Yi H, Shamoto-Nagai M, Maruyama W, Naoi M.	Overexpression of amyloid precursor protein induces susceptibility to oxidative stress in human neurobalstoma SH-SY5Y cells	Journal of Neural Transmission		In press	2006
Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MBH, Naoi M.	*N*-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti- apoptotic Bcl-2.	Journal of Neural Transmission	113 (2)	21-32	2006
Naoi M, Maruyama W, Shamoto-Nagai M, Yi H, Akao Y, Tanaka M.	Oxidative stress in mitochondria: Decision to survival and death of neurons in neurodegenerative disorders	Molecular Neurobiology	31 (1-3)	81-93	2005
Youdim MBH, Maruyama W, Naoi M	Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline	Drugs of Today	41 (6)	369- 391	2005
Youdim MBH, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T.	Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition.	Journal of Neuroscience Research	79 (1-2)	172- 179	2005
Nakagawa Y, Iinuma M, Matsuura N, Yi K, Naoi M, Nakayama T, Nozawa Y, Akao Y.	A potent apoptosis-inducing activity of a Sesquiterpene lactone arucanolide, in HL60 cells: a crucial role of apoptosis-inducing factor.	Journal of Pharmacological Science	97 (2)	242- 252	2005

Suzuki, J., Goto, S., Kato, A., Hashimoto, C., Miwa, N., Takao, S., Ishida, T., Fukuoka, A., Nakayama, H., Doi, K., Isowa, K.	Malignant NK/T-cell lymphoma associated with simian Epstein-Barr virusinfection in a Japanese macaque (Macaca fuscata).	Experimental Animals	54	101-105	2005
Hamada, Y., Suzuki, J., Ohkura, S., Hayakawa, S.	Changes in testicularand n ipple volume related to age and seasonality in Japanese macaques (Macacafuscata), especially in the pre- and post-pubertal periods.	Primates	46	33-45	2005
Elinder, F., Akand a, N., Tofighi, R., Shimizu, S.,Tsujimo to, Y., Orrenius, S. and Ceccatelli, S.	Opening of plasma memb rane voltage-dependent ani on channels (VDAC) prec edes caspase activation in neuronal apoptosis.	Cell Death Dif f.	12	1134-1140	2005
Chen, C., Shimizu, S., Tsujimoto, Y. and Motoyama, N.	Chk2 regulates transcriptio n-independent 53-mediated apoptosis in response to DNA damage.	Biochem. Bioph ys. Res. Comm un.,	12	427-431	2005
Kamada, S., Kikka wa, U., Tsujimoto, Y. and Hunter, T.	A-kinase anchoring protei n 95 functions as a poten tial carrier for the nuclear translocation of active ca spase-3 through an enzym e-substrate like associatio n.	Mol. Cell. Biol.	12	9469-9477	2005
Tsujimoto, Y. and Shimizu, S.	Another way to die: auto phagic programmed cell d eath.	Cell Death Dif f.	12	1528-1534	2005
Nakaya Y., Yaman e T., Shiraishi H., Matsubara E., Wan g H.-Q., Sato T., Wang R., De Stroo per B., Shoji M., Komano H., Yanagi sawa K., Ihara Y., Paul E. Fraser P.E., St George-Hyslop P., and Nishimura M.	Random mutagenesisi of Presenilin 1 identifies nov el mutants exclusively ge nerating longer Amyloid β peptides	J. Biol. Chem.	280	19070-19077	2005
Shiraishi H., Marut ani T., Wang H.-Q., Maeda Y., Kur ono Y., Takashima A., Araki W., Ni shimura M., Yanagi sawa K., and Kom ano H	Reconstitution of γ-secre tase by truncated presenili n (PS) fragments revealed that PS C-terminal trans membrane domain is criti cal for formation of γ-s ecretase complex	Genes to Cells	11	83-93	2006

Nogalska A., Engel W.K., Mcferrin J., Kokame K., Komano H., and Askanas V.	Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulumn stress-induced cultured human muscle fibers	J. Neurochem.	96	1491-1499	2006
Araki W., Saito S., Takahashi-Sasakii N., Shiraishi H., Komano H., and Murayama K.S.	Characterization of APH-1 mutants with a disrupted transmembrane GxxxG motif	J. Mol. Neurosci.	印刷中		2006
Hashimoto M, Nitta A, Fukumitsu H, Nomoto H, Shen L, Furukawa S.	Involvement of glial cell line-derived neurotrophic factor in activation processes of rodent macrophages.	J Neurosci Res.	5;79	476-487	2005
Miyoshi M, Nadai M, Nitta A, Ueyama J, Shimizu A, Takagi K, Nabeshima T, Takagi K, Saito K, Hasegawa T.	Role of tumor necrosis factor-alpha in down-regulation of hepatic cytochrome P450 and P-glycoprotein by endotoxin.	Eur J Pharmacol.	10;507	229-237	2005
Hashimoto M, Nitta A, Fukumitsu H, Nomoto H, Shen L, Furukawa S.	Inflammation-induced GDNF improves locomotor function after spinal cord injury.	Neuroreport	8;16	99-102	2005
Ishikawa K., Nitta A., Mizoguchi H., Mohri A., Murai R., Miyamoto Y., Noda Y., Kitaichi K., Yamada K., and Nabeshima T.	Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain	Int J Neuropsychopharmacol	7	1-9	2005
Mizuno T., Kuno R., Nitta A., Nabeshima T., Zhang G., Kawanokuchi J., Wang J., Jin S., Takeuchi H., and Suzumura A.,	Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes.	Brain Res.	1066	75-85	2005
Enomoto T., Noda Y., Mouri A., Shin E.J., Wang D., Murai R., Hotta K., Furukawa H., Nitta A., Kim H.C., and Nabeshima T.	Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-D-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine.	Mol Pharmacol.	68	1765-1744	2005
Yan Y., Nitta A., Mizoguchi H., Yamada K., and Nabeshima T.,	Relapse of methamphetamine-seeking behavior in C57BL/6J mice demonstrated by a reinstatement procedure involving intraveno	Behav Brain Res.	15	145-175	2005

	us self-administration.				
Cen X., Nitta A., Ohya S., Zhao Y. , Ozawa N., Mouri A., Ibi D., Wang L., Suzuki M., Saito K., Ito Y., Kawagoe T., Noda Y. , Ito Y., Furukawa S., and Nabeshima T.,	An analogue of dipeptide-like structure of FK506 increases GDNF expression through CREB activated by Hsp90/Akt signaling pathway.	J. Neurosci.	in press		

Oxidative Stress, Inflammation, and Health

edited by

Young-Joon Surh
Lester Packer

Taylor & Francis
Taylor & Francis Group

Boca Raton London New York Singapore

A CRC title, part of the Taylor & Francis imprint, a member of the Taylor & Francis Group, the academic division of T&F Informa plc.

23

Neuroprotection by Rasagiline and Related Propargylamines Is Mediated by Suppression of Mitochondrial Death Signal and Induction of Antiapoptotic Genes

WAKAKO MARUYAMA

Laboratory of Biochemistry and Metabolism, Department of Basic Gerontology, National Institute for Longevity Sciences, Aichi, Japan

ATSUMI NITTA

Department of Pharmacy, Nagoya University School of Medicine, Nagoya, Japan

YUKIHIRO AKAO and MAKOTO NAOI

Gifu International Institute of Biotechnology, Gifu, Japan

ABSTRACT

In neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases, apoptosis is a major type of neuronal cell death, and the apoptotic cascade has been proposed to be a target of "neuroprotection" through preventing and delaying cell death.

A series of propargylamine derivatives have been confirmed to protect neurons against cell death induced by various insults. The mechanism underlying the neuroprotection has been clarified by use of rasagiline [*N*-propargyl-1(*R*) aminoindan], the most potent propargylamine, and human dopaminergic neuroblastoma SH-SY5Y cells.

Rasagiline stabilizes the mitochondrial membrane potential, $\Delta\Psi_m$, prevents permeability transition, and suppresses the activation of following apoptotic signal transduction; release of cytochrome *c*, activation of caspase 3, nuclear translocation of glyceraldehydes-3-phosphate dehydrogenase (GAPDH) and fragmentation of nuclear DNA. In addition, rasagiline induces antiapoptotic Bcl-2 and glial cell-line-derived neurotrophic factor (GDNF) in SH-SY5Y cells.

In this review, we summarize our recent advances in understanding the mechanism behind the neuroprotection by rasagiline. Rasagiline was found to activate NF-κB, a nuclear transcription factor playing a critical role in determining cell death/survival pathway. Rasagiline activated IκB kinase, and active NF-κB p65 subunit was translocated into nuclei. In addition, gene array analysis revealed that rasagiline increased the expression of the genes coding mitochondrial energy synthesis, apoptosis, transcription, kinases, and ubiquitin–proteasome system, the involvement of which has been proposed in neuronal cell death and accumulation of inclusion bodies in various neurodegenerative disorders. These results are discussed as they concern the possibility of neuroprotection by propargylamines in Parkinson's and Alzheimer's diseases.

I. NEUROPROTECTION BY PROPARGYLAMINES: INTRACELLULAR MECHANISM

The development of "neuroprotective drugs" is now gathering attention in order to slow down the disease progress and improve quality of life of the patients with neurodegenerative disorders, such as Parkison's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis. On the other hand, activation of mitochondria-dependent apoptotic signal is considered to account for cell death in neurodegenerative disorders (1,2) and well-conserved and -regulated apoptotic cascade has been proposed to be a target of neuroprotection (3,4). Using the cellular and animal models of neurodegenerative disorders, several candidates of neuroprotective agents have been proposed: antioxidants, inhibitors of monoamine oxidase [MAO, monoamine: oxygen oxidoreductase (deaminating), EC 1.4.3.4], anti-inflammatory drugs, drugs interfering glutamate excitotoxicity, and growth factors (5–8). These candidates are expected to intervene the death signal transduction and protect neurons from degeneration.

N-Propargyl-1(*R*)-aminoindan (rasagiline) is an inhibitor of type B MAO (MAO-B) (9,10), and has been developed as an anti-Parkinson drug (11–13). The phase III clinical trial of rasagiline was now finished for the treatment of parkinsonian patients. The neuroprotective potency of rasagiline has been proved in vivo using animal models induced by neurotoxins, excitotoxicity toxins, ischemic, and closed brain injury (14–16). However, in clinical studies, it requires further results to prove the neuroprotective potency, in addition to the previously confirmed symptomatic effects (17).

Also in vitro rasagiline has been shown to reduce glutamate toxicity in cultured hippocampal neurons (13) and to prolong survival of cultured, serum-derived rat fetal mesencephalic cells (18). The structure–activity relationship suggested that the neuroprotective effect of rasagiline and related compounds did not depend on the MAO inhibitory property, as shown by neuroprotection by the enantiomer of rasagiline, *N*-propargyl-1(*S*-)aminoindan (TVP-1022), which

was 100-fold less active as MAO inhibitor (14). We studied the mechanism behind neuroprotection of rasagiline against cell death induced in human neuroblastoma SH-SY5Y cells by peroxynitrite and neurotoxins, *N*-methyl(*R*)salsolinol [*N*M(*R*)Sal] and 6-hydroxydopamine, as a cellular PD model (19,20).

Apoptosis is a death process observed in neurons after exposure to neurotoxins, increased oxidative stress, excitotoxins, and withdrawal of neurotrophic factors. The intracellular process of apoptosis induced by *N*M(*R*)Sal in SH-SY5Y cells was elucidated as follows. Binding of *N*M(*R*)Sal to mitochondrial outer membrane initiates mitochondrial permeability transition (mPT), opening a megachannel called mPT pore, which induces rapid reduction of mitochondrial membrane potential, $\Delta\Psi_m$, and swelling of mitochondria. Then the following apoptotic cascade is activated: release of cytochrome *C* and other apoptosis-inducing factors from mitochondria to cytoplasm, activation of caspase 3, an executer of apoptosis, and translocation of glyceraldehydes-3-phosphate dehydrogenase [GAPDH, D-glyceraldehydes-3-phosphate:NAD; oxidoreductase (phosphorylating), EC 1.2.1.12] from cytoplasm to nuclei. In the final, fragmentation and condensation of nuclear DNA are induced, as shown by nuclei with condensed chromatin and fragmented DNA, and ladder formation of fragmented oligonucleosomal DNA by agarose gel electrophoresis (21,22). Figure 1 summarizes the activation of apoptotic cascade induced by *N*M(*R*)Sal and other stimuli.

A series of propargylamines, including rasagiline, (−) deprenyl, and aliphatic (*R*)*N*-(2-heptyl)-*N*-methylpropargyl-amine (*R*-2HMP) inhibits the activation of apoptotic cascade and protects SH-SY5Y cells against apoptosis. The chemical structures of propargylamines with antiapoptotic potency are shown in Fig. 2. As summarized in Fig. 3, these propargylamines prevent collapse in $\Delta\Psi_m$, in isolated mitochondria (23), and SH-SY5Y cells (19), and following activation of apoptotic cascade. These results are quite similar to those observed in SH-SY5Y cells with overexpression of antiapoptotic Bcl-2 protein family, suggesting the involvement of Bcl-2 and related prosurvival protein. Based on these results, we examined whether rasagiline could induce genes coding antiapoptotic protein in neurons.



Figure 1 Mitochondria-dependent apoptosis cascade activated by an endogenous neurotoxin, *N*M(*R*)Sal in Sh-SY5Y cells.

II. INDUCTION OF NEUROPROTECTIVE PROTEIN

As mentioned above, some kinds of proteins have been proposed to alleviate neuronal loss through suppression of oxidative stress, prevention of apoptotic signal transduction, and promotion of cell survival. Rasagiline, (−) deprenyl, and aliphatic propargylamines were found to increase the activity of antioxidative enzymes, superoxide dismutase (SOD), and catalase, in the rat brain after the continuous injection (24,25). (−) Deprenyl and desmethyldeprenyl were reported to increase mRNA level of SOD 1 and 2, Bcl-2 and Bcl-xL, nitric oxide synthase, c-JUN, and nicotinamide adenine dinucleotide dehydrogenase in PC12 cells (26).

Bcl-2 and related proteins are known to prevent mPT induction and activation of apoptotic cascade in a variety of physiological and pathological contexts (27,28). The family of Bcl-2-related proteins constitutes one of most relevant regulatory gene



N-Propargl-1(*R*)-aminoindan
(Rasagiline)



(-)Deprenyl (selegiline)



N-(2-Heptyl)-*N*-methylpropagylamine
(2-HMP)

Figure 2 Chemical structures of propargylamines with neuroprotective potency. Rasagiline contains a cyclic benzylamine structure,

products against apoptosis. We found that rasagiline increased mRNA and protein levels of *bcl-2* and *bcl-xL* in SH-SY5Y cells.

Neurotrophic factors, such as nerve growth factor, glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and ciliary neurotrophic factor (CDTF), have been proposed as agents preventing neuronal loss (29,29a). Recently, we found that rasagiline induced mRNA and protein of GDNF, which protects or promotes survival of dopamine neurons selectively.

These results suggest that rasagiline may activate an intracellular signal transduction common for induction of genes coding these antiapoptotic proteins, antioxidative enzymes, antiapoptotic Bcl-2 family protein, and GDNF.



Figure 3 The summary of the mechanism underlying neuroprotection by propargylamines.

II.A. Induction of Bcl-2 by Rasagiline

Bcl-2 family proteins play key roles in regulating apoptosis (28) and they may be either death antagonists (Bcl-2, Bcl-xL, Bfl-1, A1, and Mcl-1) or agonists (Bax, Bak, Bad, Bid, Bik, and Hrk). The proteins form homo- or heterodimers between anti- and proapoptotic members and determine cellular sensitivity to apoptotic stimuli by titrating one another's function. Bcl-2 is mainly localized in the mitochondrial inner membrane and it can promote survival in neurons and other cells undergoing apoptosis (27). Overexpression of Bcl-2 protects various neuron paradigms in vivo and in vitro from death induced by neurotoxins and other insults. Bcl-2 regulates apoptosis induced by *N*M(*R*)Sal, as proved by preventing apoptosis in Bcl-2-overexpressed SH-SY5Y cells (19) and also $\Delta\Psi_m$ decline in isolated mitochondria prepared from liver of Bcl-2 overexpressed mice (23). These results suggest that Bcl-2 protein in mitochondria may mediate the neuroprotection by rasagiline. The induction of mRNA and protein of antiapoptotic Bcl-2 family proteins was examined in

SH-SY5Y cells either by reverse transcription (RT)-PCR or Western blot analysis.

Rasagiline was prepared as reported previously (9) and kindly donated by Teva Pharmaceutical (Netanya, Israel). SH-SY5Y cells were cultured in the presence of various concentrations (10 μM–1 pM) of rasagiline for 24 hr or for a various incubation time with 100 nM rasagiline. The whole cells were gathered and the total RNA was extracted by the phenol/guanidinium thiocyanate method. cDNA was generated by reverse transcription of the total RNA, and the cDNA fragments were amplified using the PCR primers. PCR products were analyzed by electrophoresis on 3% agarose gels, and β-actin cDNA was used as an internal standard. The mRNA levels of *bcl-2* and *bcl-xL* were quantified by computer-assisted image analysis using NIH imaging software.

Rasagiline was confirmed to enhance expression of *bcl-2* and related genes. Reverse transcription-PCR analyses revealed increased levels of *bcl-2* mRNA after treatment with 100 nM rasagiline in a time-dependent way (Fig. 4A). The *bcl-2* mRNA levels began to increase after 3 hr of the treatment with rasagiline and the increase continued further to about threefold at 24 hr. Western blot analyses showed that Bcl-2 protein level increased from 6 to 24 hr of the treatment. Figure 4B shows that rasagiline increases *bcl-2* mRNA level, but not *bax* mRNA at 100–1 nM. Figure 5A shows the quantitative analyses of *bcl-2* mRNA levels increased by rasagiline treatment, and the relative value of *bcl-2* mRNA to *β-action* mRNA increased to about 150% of control after incubation with rasagiline. Among *bcl-x* isoforms, a 337 base pair fragment corresponding to the *bcl-xL* also increased by 100 nM rasagiline treatment, whereas the mRNA levels of *mcl-2* and *bax* were not affected (Fig. 5B). Other MAO-A and -B inhibitors, clorgyline, and pargyline, did not affect the mRNA level at the concentrations examined (10 μM–1 pM). These results clearly indicate that rasagiline induced prosurvival Bcl-2 protein family, but not apoptosis-promoting Bax family.



Figure 4 Effect of rasagiline on levels of mRNA and protein of *bcl-2* family. (A) SH-SY5Ycells treated with 100 nM rasagiline for 3, 6, and 24 hr and the mRNA levels were assayed by RT-PCR and the protein levels by immunoblot analysis using antibody against Bcl-2 protein. (B) The cells were treated with 100, 10, and 1 nM rasagiline for 24 hr and the *bcl-2* and *bax* mRNA were assayed by RT-PCR.

II.B. Induction of Glial Cell-Line-Derived Neurotrophic Factor

Glial cell-line-derived neurotrophic factor is a member of the transforming growth factor-β superfamily and effectively protects dopaminergic neurons against cell death in various animal models of PD prepared with 6-hydroxydopamine and



Figure 5 The effects of rasagiline and sulfasalazine on *bcl-2* and related genes. SH-SY5Y cells were incubated with rasagiline for 24 hr and mRNA was extracted and applied for RT-PCR. (A) The level of *bcl-2* mRNA in the cells treated with various concentration of rasagiline was quantified by NIH imaging software and compared to control cells without the treatment of rasagiline. (B) The effect of rasagiline and the pretreatment with sulfasalazine. Rasagiline at 100 nM increased mRNA of *bcl-2* and *bcl-xL* but did not affect

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (30,31). Since GDNF and other neurotrophic factors cannot penetrate into the brain through the blood–brain barrier, several trials have been reported to deliver GDNF in the substantia nigra by direct administration (32,33), gene therapy (34,35), and cell implant (36,37). There were several controversial results about the effectiveness of GDNF supplement therapy in parkinsonian patients, mostly because of the technical difficulties to deliver GDNF to nigral dopamine neurons. However, recently GDNF injected directly to the putamen improved the symptoms in a part of parkinsonian patients (38). We confirmed that rasagiline induced GDNF in SH-SY5Y cells and the mechanism was also clarified.

The effect of rasagiline on levels of GDNF mRNA was studied by RT-PCR, and on those of GDNF protein was quantified using the enzyme immunoassay (EIA), as reported previously (39,40). Glial cell-line-derived neurotrophic factor

Table 1 Effect of Rasagiline and Sulfasalazine on GDNF Protein Level in SH–SY5Y Cells

SH–SY5Y cells treated with		
Rasagiline (μM)	Sulfasalazine (mM)	GDNF (pg/mL)
0	0	0.446 ± 0.213
0	0.1	4.83 ± 2.26
1	0	2.02 ± 1.82
0.1	0	100.6 ± 27.3[a]
0.01	0	3.84 ± 2.50
0.1	0.1	4.46 ± 2.37[b]

SH–SY5Y cells were incubated with rasagiline with or without pretreatment of 0.1 mM sulfasalazine for 3 hr and GDNF was measured by EIA as described in "Materials and Methods".

[a]The difference was significant from the cells without treatment.

[b]The difference was significant from the cells treated with 0.1 μM of rasagiline alone.

mRNA was virtually not detectable in SH-SY5Y cells, but after the treatment with 0.1 μM of rasagiline for 3 hr considerable amount of GDNF mRNA was detected. As summarized in Table 1, the amount of GDNF protein in the cells increased most markedly after being treated with 0.1 μM of rasagiline. The GDNF protein was less than 1 pg/mL before rasagiline treatment, but it increased more than 100 pg/mL after the treatment for 3 hr (Table 1).

II.C. Activation of NF-κB Transcription Factor by Rasagiline

NF-κB is the common transcription factor to induce antiapoptotic *bcl-2*, neurotrophic GDNF, and antioxidative SOD, all of which were increased by rasagiline (24,40,41). As shown in Fig. 6, NF-κB consists of two subunits of 65 kDa (p65: RelA) and 50 kDa (p50) or 52 kDa (p52), and is sequestered in the cytoplasm as an inactive complex with NF-κB inhibitory subunit (IκB). Upon stimulation, IκB is phosphorylated, dissociated from the complex, and degraded by the ubiquitin–proteasome system. This reaction allows translocation of free, active NF-κB complex into nuclei, where it binds to specific DNA



Figure 6 The mechanism behind the activation of NF-κB. By the various exogenous and endogenous stimuli, IκB kinase is activated and it phosphorylates IκB in the inactive NF-κB complex. Phosphorylated IκB is degraded by ubiquitin–proteasome system and active NF-κB dimmer consists of 65 kDa (p65: RelA) and 50 kDa (p50) or 52 kDa (p52) translocates into the nuclei to bind κB sites.

motifs in the promoter/enhancer regions of target genes and activates transcription.

The translocation of activated p65 subunit was studied by Western blot analysis of the subcelluar fractions of SH-SY5Y cells after treatment with 1 and 0.1 μM of rasagiline for 30 and 60 min. Rasagiline treatment increased p65 subunit in the nuclear fraction in a time- and dose-dependent way, whereas that in the cytoplasmic fraction decreased. The translocation of activated NF-κB was also examined by immunohistochemistry using the p65 antibody (Fig. 7B), and nuclear staining with Hoechst 33342 (Fig. 7A). After 3 hr treatment with rasagiline, nuclear translocation of p65 was confirmed by merging the two figures (Fig. 7C).



Figure 7 Nuclear translocation of p65 NF-κB subunit by the treatment with rasagiline. SH-SY5Y cells were treated with 0.1 μM of rasagiline for 3 hr and fixed in paraformaldehyde. The sample was stained with Hoechst 33342 nuclear staining (A) and immunostaining using anti-p65 antibody (B). (C) shows the merge of (A) and (B).

The activation of NF-κB and the increased binding activity were examined also by ELISA, using NF-κB p65 transcription assay kit according to Kretz-Remy et al. (42). The principle of this assay is to measure the binding of activated NF-κB p65 to an oligonucleotide containing the NF-κB consensus-binding site. Rasagiline increased the binding activity of NF-κB p65 to the oligonucleotides and it was competitively inhibited by pretreatment with wild oligonucleotide containing the NF-κB binding site, but not the mutated one, indicating the selective binding to the NF-κB binding site.

The involvement of phosphorylation of IκB, an inhibitory subunit on the activation of NF-κB, was studied by use of sulfasalazine, an inhibitor of IκB kinase as summarized in Table 1. Also NF-κB binding assay showed that sulfasalazine suppressed the rasagiline-induced increase in the binding capacity, again suggesting the involvement of IκB kinase–NF-κB axis. In addition, Western blot analysis of the

subcellular fractions of rasagiline-treated cells demonstrated that sulfasalazine reduced nuclear translocation of activated p65 subunit.

Sulfasalazine abolished the increase of mRNA of *bcl-2* and *bcl-xL* as in the case with GDNF, suggesting the involvement of NF-κB transcription factor in the induction of neuroprotective genes in common (Fig. 5B).

II.D. Gene Expression by Rasagiline Detected by DNA Array Analyses

SH-SY5Y cells were treated with 0.1 μM of rasagiline for 6, 12, and 24 hr and mRNA was extracted and reverse-transcripted with biotylated dUTP (Roche Diagnostics) and gene-specific primer mixture reported as the manufacture's instruction (Takara Bio Co., Otsu, Japan). The probes were hybridized to a cDNA expression array membrane containing more than 2000 genes related to apoptosis, cell survival, and transcription. The relative expression level of a given mRNA was assessed by normalizing to a housekeeping gene, β-actin, provided on the membrane and comparing to the control values obtained by the cells without treatment of rasagiline.

The gene induction was widely surveyed by gene array analysis system to compare the level of mRNA relating apoptosis-survival signal in the cells with or without the treatment of rasagiline (Table 2). Rasagiline increased mRNA of the genes relating mitochondria and ATP synthesis, ubiquitin–proteasome system and Bcl-2 in first 6 hr and then, genes relating signal transduction and transcription, including a series of kinases and NF-κB, were increased after 24 hr.

III. DISCUSSION

This paper reports that rasagiline induces neuroprotective genes in SH-SY5Y cells through the activation of transcription factor NF-κB. Rasagiline is a selective inhibitor of MAO-B, but its neuroprotective effect cannot be ascribed to MAO inhibition, because SH-SY5Y cells do not contain MAO-B. Recent

Table 2 Gene Induction in SH–SY5Y Cells by Rasagiline

Cells incubated with rasagiline for 6 hr	12 hr	24 hr
Metabolism and ATP synthesis		
Cytochrome c oxidase	ATP synthase	*Cell signaling*
NADH-coenzyme Q reductase	Cytochrome c oxidase	Tumor protein 53-binding protein
ATP synthase	ATP binding protein	PTK2 protein tyrosine kinase 2
Aconitase		MAP kinase 6
		LPS-induced TNF-alpha factor
		TNF receptor member 6
		PTK2 protein tyrosin kinase 2
		MAP kinase kinase 6
		TNFRSF-interacting serine/threonine kinase
		Tumor protein 53-binding protein
		Cyclin-dependent tyrosine kinase 5 (p35)
		Neurotrophic tyrosine kinase receptor
Apoptosis		
Bcl-2	Apoptosis inhibitor 2	Bcl-2
	Apoptosis inhibitor	
	Bcl-2 like	
	Neuronal apoptosis inhibitory protein	
Transcription		
	Mitochondrial transcription factor A	Transcription factor Dp-1, Dp-2
	Transcription elongation factor B	TRAF-associated NFkB activator
		E2F transcription factor 5, 3
		P130-binding NFkB
Intracellular protein degrading		
Proteasome subunit, b type 3, 1, 7, 5	Ubiquitin-conjugating enzyme E2N	
Ubiquitin fusion degradation 1 like	Ubiquitin fusion degradation 1 like	
	Proteasome subunit, b type 3, 1	